Northwest Bioth Cmn (NWBO) 0.47 $NWBO
Research Reports Coverage on Biotech Stocks -- Northwest Biotherapeutics, Radius Health, Spectrum Pharma, and Kite Pharma
PR Newswire - Mon Sep 12, 7:05AM CDT
Biotechnology has seen some substantial declines since the start of this year due to political comments on pricing, which is expected to persist for an uncertain period of time. Some companies in the industry, however, signal recovery and growth potential given M&A activities and the development of new methodologies and platforms. This morning, Stock-Callers.com has initiated research reports on the following equities: Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Radius Health Inc. (NASDAQ: RDUS), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Kite Pharma Inc. (NASDAQ: KITE). These stocks research reports can be downloaded now by simply registering for free at:
RDUS: 55.12 (+0.63), NWBO: 0.47 (+0.05), KITE: 57.63 (+2.26), SPPI: 4.82 (-0.03)
NASDAQ Accepts NW Bio Remediation Plan For Shares and Warrants Previously Issued to Cognate BioServices
PR Newswire - Tue Sep 06, 7:55AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" or the "Company"
, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that Nasdaq has accepted NW Bio's proposed remediation plan to resolve Nasdaq's finding, previously disclosed by the Company, that NW Bio failed to comply with certain Nasdaq listing rules with regard to certain securities issuances to Cognate BioServices, Inc. ("Cognate" . As a result of this acceptance, Nasdaq has notified the Company that it has regained compliance with these rules, and this matter is now closed.
NWBO: 0.47 (+0.05)
NW Bio Announces Scientific Advisory Board
PR Newswire - Mon Jun 13, 8:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immunotherapies for solid tumor cancers, announced its Scientific Advisory Board (SAB) comprised of leading experts in immunotherapies and oncology from both the U.S. and Europe.
NWBO: 0.47 (+0.05)
NW Bio Announces Operations Updates
PR Newswire - Mon May 02, 4:00PM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today an operations update in regard to its Phase I and II Trials, Scientific Advisory Board and Nasdaq compliance.
NWBO: 0.47 (+0.05)
NW Bio Presenting At Phacilitate Immunotherapy World Forum
PR Newswire - Mon Jan 25, 11:43AM CST
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that CEO Linda Powers will chair the morning plenary session and present at the Phacilitate Immunotherapy World Forum on Tuesday, January 26, 2016, at the Grand Hyatt Hotel in Washington DC.
NWBO: 0.47 (+0.05)
NW Bio Announces Appointment Of Two New Independent Directors With Biotech/Pharma Expertise and Cybersecurity/Investigations Expertise
PR Newswire - Mon Jan 25, 8:30AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is expanding its Board of Directors through the appointment of Ms. Susan Bayh and Ambassador Cofer Black as independent Directors. Neither Ms. Bayh nor Ambassador Black has worked with the Company previously.
NWBO: 0.47 (+0.05)
Biotechnology Equity Movers and Shakers -- Agenus, Xenoport, Akebia Therapeutics, and Northwest Biotherapeutics
ACCESSWIRE - Mon Jan 11, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / January 11, 2016 / Park Lane Advisor has initiated coverage on the following equities: Agenus Inc. (NASDAQ: AGEN), Xenoport Inc. (NASDAQ: XNPT), Akebia Therapeutics Inc. (NASDAQ: AKBA), and Northwest Biotherapeutics Inc. (NASDAQ: NWBO). Free research report on Agenus can be accessed at http://www.parklaneadvisor.com/ On Friday, January 08, 2016, the NASDAQ Composite ended at 4,643.63, down 0.98%, the Dow Jones Industrial Average declined 1.02%, to finish the day at 16,346.45, and the S&P 500 closed at 1,922.03, down 1.08%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
AGEN: 6.77 (+0.17), NWBO: 0.47 (+0.05), AKBA: 8.98 (+0.40), XNPT: 7.07 (+0.05)
NW Bio Issues Statement on Adverse Market Conditions And NW Bio Stock Decline
PR Newswire - Fri Jan 08, 8:15AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today issued the following statement addressing the sharp decline in the Company's stock:
NWBO: 0.47 (+0.05)
NW Bio Announces Closing Of Registered Direct Offering of $12.6 Million
PR Newswire - Thu Dec 24, 3:29PM CST
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of its previously-announced registered direct placement with healthcare focused institutional investors, for gross proceeds of $12.6 million on the terms previously announced.
NWBO: 0.47 (+0.05)
Why Northwest Biotherapeutics, Accuray, and U.S. Steel Slumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Dec 23, 5:14PM CST
Steelmakers like U.S. Steel underperformed the market today. Image: U.S. Steel. Energy stocks dominated the news Wednesday, as the price of crude oil bounced off their recent lows and raised hopes that the long slide for the industry could finally...
NWBO: 0.47 (+0.05), ARAY: 5.45 (-0.01), X: 15.91 (-0.15)
NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $12.6 MILLION
PR Newswire - Wed Dec 23, 8:00AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with healthcare focused institutional investors for a registered direct offering with gross proceeds of $12.6 million. In the offering, the Company is selling an aggregate of 3.5 million shares of common stock at a purchase price of $3.60 per share. The investors will also receive warrants to purchase up to 1.75 million shares of common stock with an exercise price of $4.50 per share. The warrants will become exercisable on the 6-month anniversary of issuance, and will have an exercise period of 5 years following the initial exercise date. The placement is expected to close on or about December 29, 2015, subject to satisfaction of customary closing conditions.
NWBO: 0.47 (+0.05)
Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020
M2 - Tue Dec 22, 6:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/q3dfhj/global_cancer) has announced the addition of the "Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020" report to their offering. The cancer industry is one of the most lucrative business worldwide. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Cancer vaccines can be broadly classified into two segments: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer. With the rising incidences of cancer and limited treatment options, physicians are being forced to look for precautionary vaccines beyond the conventional treatments. As a result, many companies are now investing in developing prophylactic and therapeutic vaccines to curb this deadly disease. In the global cancer vaccines market, the prophylactic vaccines segment account for maximum share of the market. However, the market share of prophylactic vaccines is likely to decline continuously during the forecasting period due to the increasing uptake of therapeutic vaccines. The market share of therapeutic cancer vaccines is anticipated to increase during the forecasting period. Key Topics Covered: 1. Executive Summary 2. Global - Cancer Vaccines Market and Forecast to 2020 3. Global - Cancer Vaccines Market Share and Forecast to 2020 4. Global - Prophylactic Cancer Vaccines Market and Forecast to 2020 5. Global - Therapeutics Cancer Vaccines Market and Forecast to 2020 6. Cancer Vaccines Market - Regional Analysis 7. Global Cancer Vaccines Market - Major Deals 8. Global Cancer Vaccines - Funding 9. Global Cancer Vaccines Market - Pipeline Portfolio Analysis 10. Company Cancer Vaccines - Pipeline Analysis 11. Global Cancer Vaccines Market - Driving Factors 12. Global Cancer Vaccines Market - Challenges Companies Mentioned: - Aduro Biotech - Advantagene - Advaxis - Agenus - AlphaVax - Altor BioScience - Argos Therapeutics - AVAX Technologies - Bavarian Nordic - Biothera - Celldex Therapeutics - CureVac - Galena Biopharma - Genexine - GlobeImmune - Gradalis - Heat Biologics - Immatics - ImmunoCellular Therapeutics - Inovio Pharmaceuticals - ISA Pharmaceuticals - Juvaris Biotherapeutics - NewLink Genetics - Northwest Biotherapeutics - NovaRx - OncoThyreon - Oncovir - Oxford BioMedica - Prima BioMed - Sotio - Transgene - Ubivac - Vaccinogen - Vaxon Biotech For more information visit http://www.researchandmarkets.com/research/q3...bal_cancer
HTBX: 1.39 (unch), INO: 9.24 (-0.24), ARGS: 4.90 (+0.03), NWBO: 0.47 (+0.05), ADRO: 14.67 (+0.64), CLDX: 3.65 (-0.05), NLNK: 10.77 (+0.14), GALE: 0.32 (-0.01), IMUC: 0.12 (unch)
Robbins Arroyo LLP: Northwest Biotherapeutics, Inc. (NWBO) Misled Shareholders According to a Recently Filed Class Action
BusinessWire - Mon Dec 21, 3:07PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed in the U.S. District Court for the District of Maryland. The complaint alleges that officers and directors of Northwest Biotherapeutics, Inc. (NASDAQCM: NWBO) violated the Securities Exchange Act of 1934 between March 8, 2013 and August 20, 2015, by making materially false and misleading statements about Northwest Bio's business prospects. Northwest Bio is a biotechnology company that discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
NWBO: 0.47 (+0.05)
NW Bio Announces Annual Meeting Results, Re-Election of Directors
PR Newswire - Mon Dec 21, 12:05PM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the results of its 2015 Annual Shareholder Meeting, held on Friday, December 18, 2015. There were three matters subject to a shareholder vote: the re-election of Linda Powers and Dr. Navid Malik as Directors for 3-year terms, and the re-appointment of the Company's auditors, Marcum LLP. NW Bio has a staggered Board, with one or two of the current five Directors up for re-election each year, and with each election being for a 3-year term.
NWBO: 0.47 (+0.05)
Pre-Market Pulse on Biotechnology Stocks -- Inovio Pharma, Vital Therapies, Regulus Therapeutics, and Northwest Biotherapeutics
ACCESSWIRE - Mon Dec 21, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / December 21, 2015 / Park Lane Advisor has initiated coverage on the following equities: Inovio Pharmaceuticals Inc. (NASDAQ: INO), Vital Therapies Inc. (NASDAQ: VTL), Regulus Therapeutics Inc. (NASDAQ: RGLS), and Northwest Biotherapeutics Inc. (NASDAQ: NWBO). Free research report on Inovio Pharma can be accessed at http://www.parklaneadvisor.com/ On Friday, December 18, 2015, the NASDAQ Composite ended at 4,923.08, down 1.59%, the Dow Jones Industrial Average declined 2.10%, to finish the day at 17,128.55, and the S&P 500 closed at 2,005.55, down 1.78%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
INO: 9.24 (-0.24), NWBO: 0.47 (+0.05), VTL: 5.86 (+0.01), RGLS: 3.23 (-0.11)
5 Stocks We're Staying Away From in 2016
Brian Feroldi, Selena Maranjian, Sean Williams, Brian Stoffel, and Jason Hall, The Motley Fool - Motley Fool - Sun Dec 20, 7:11PM CST
Image by PeteLinforth via Pixabay. Investing in the stock market is one of the best wealth-building tools available to individual investors, as the returns provided from the market's best growth companies can be jaw dropping . Still, finding those...
PM: 98.84 (-0.91), NWBO: 0.47 (+0.05), GLD: 125.06 (-0.31), BBY: 38.00 (+0.32), SHLD: 12.12 (+0.06), PDLI: 3.17 (+0.05)
Metastatic Ovarian Cancer Pipeline Review, H2 2015 - 9 Companies & 13 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/tp9jps/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellceutix Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Immune Design Corp. - Millennium Pharmaceuticals, Inc. - Natco Pharma Limited - Northwest Biotherapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - VG Life Sciences, Inc. Drug Profiles - DCVax-Direct - DCVax-L - Drugs for Metastatic Ovarian Cancer - E-7449 - emactuzumab - G-305 - hydroxychloroquine sorafenib tosylate - KM-3174 - LV-305 - NRCAN-019 - orteronel - SM-276001 - Vaccine for Oncology For more information visit http://www.researchandmarkets.com/research/tp9jps/metastatic
IMDZ: 6.57 (+0.32), NWBO: 0.47 (+0.05)
Where We Are Headed - Featured Research on Bancorp Inc., Northwest Biotherapeutics, Xerium Technologies, and BioPharmX
ACCESSWIRE - Wed Dec 16, 7:23AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Bancorp Inc. (NASDAQ: TBBK), Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Xerium Technologies Inc. (NYSE: XRM) and BioPharmX Corp (NYSE: BPMX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 0.47 (+0.05), XRM: 8.32 (+0.15), TBBK: 6.11 (unch), BPMX: 0.65 (-0.04)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
BusinessWire - Wed Dec 16, 6:00AM CST
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and finding new ways to use the body's immune system to fight cancer.
NWBO: 0.47 (+0.05), TSRO: 104.11 (+5.32), CTMX: 15.48 (+0.37), NK: 9.23 (+0.33), CNCR: 25.65 (+0.10), SRNE: 6.93 (+0.12), XNCR: 24.63 (+0.59), ONTY: 1.21 (+0.02), CYAD: 21.45 (-1.04)
Research Reports Coverage on Biotech Stocks -- Northwest Biotherapeutics, Radius Health, Spectrum Pharma, and Kite Pharma
PR Newswire - Mon Sep 12, 7:05AM CDT
Biotechnology has seen some substantial declines since the start of this year due to political comments on pricing, which is expected to persist for an uncertain period of time. Some companies in the industry, however, signal recovery and growth potential given M&A activities and the development of new methodologies and platforms. This morning, Stock-Callers.com has initiated research reports on the following equities: Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Radius Health Inc. (NASDAQ: RDUS), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Kite Pharma Inc. (NASDAQ: KITE). These stocks research reports can be downloaded now by simply registering for free at:
RDUS: 55.12 (+0.63), NWBO: 0.47 (+0.05), KITE: 57.63 (+2.26), SPPI: 4.82 (-0.03)
NASDAQ Accepts NW Bio Remediation Plan For Shares and Warrants Previously Issued to Cognate BioServices
PR Newswire - Tue Sep 06, 7:55AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" or the "Company"
, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that Nasdaq has accepted NW Bio's proposed remediation plan to resolve Nasdaq's finding, previously disclosed by the Company, that NW Bio failed to comply with certain Nasdaq listing rules with regard to certain securities issuances to Cognate BioServices, Inc. ("Cognate" . As a result of this acceptance, Nasdaq has notified the Company that it has regained compliance with these rules, and this matter is now closed. NWBO: 0.47 (+0.05)
NW Bio Announces Scientific Advisory Board
PR Newswire - Mon Jun 13, 8:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immunotherapies for solid tumor cancers, announced its Scientific Advisory Board (SAB) comprised of leading experts in immunotherapies and oncology from both the U.S. and Europe. NWBO: 0.47 (+0.05)
NW Bio Announces Operations Updates
PR Newswire - Mon May 02, 4:00PM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today an operations update in regard to its Phase I and II Trials, Scientific Advisory Board and Nasdaq compliance. NWBO: 0.47 (+0.05)
NW Bio Presenting At Phacilitate Immunotherapy World Forum
PR Newswire - Mon Jan 25, 11:43AM CST
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that CEO Linda Powers will chair the morning plenary session and present at the Phacilitate Immunotherapy World Forum on Tuesday, January 26, 2016, at the Grand Hyatt Hotel in Washington DC. NWBO: 0.47 (+0.05)
NW Bio Announces Appointment Of Two New Independent Directors With Biotech/Pharma Expertise and Cybersecurity/Investigations Expertise
PR Newswire - Mon Jan 25, 8:30AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is expanding its Board of Directors through the appointment of Ms. Susan Bayh and Ambassador Cofer Black as independent Directors. Neither Ms. Bayh nor Ambassador Black has worked with the Company previously.
NWBO: 0.47 (+0.05)
Biotechnology Equity Movers and Shakers -- Agenus, Xenoport, Akebia Therapeutics, and Northwest Biotherapeutics
ACCESSWIRE - Mon Jan 11, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / January 11, 2016 / Park Lane Advisor has initiated coverage on the following equities: Agenus Inc. (NASDAQ: AGEN), Xenoport Inc. (NASDAQ: XNPT), Akebia Therapeutics Inc. (NASDAQ: AKBA), and Northwest Biotherapeutics Inc. (NASDAQ: NWBO). Free research report on Agenus can be accessed at http://www.parklaneadvisor.com/ On Friday, January 08, 2016, the NASDAQ Composite ended at 4,643.63, down 0.98%, the Dow Jones Industrial Average declined 1.02%, to finish the day at 16,346.45, and the S&P 500 closed at 1,922.03, down 1.08%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
AGEN: 6.77 (+0.17), NWBO: 0.47 (+0.05), AKBA: 8.98 (+0.40), XNPT: 7.07 (+0.05)
NW Bio Issues Statement on Adverse Market Conditions And NW Bio Stock Decline
PR Newswire - Fri Jan 08, 8:15AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today issued the following statement addressing the sharp decline in the Company's stock: NWBO: 0.47 (+0.05)
NW Bio Announces Closing Of Registered Direct Offering of $12.6 Million
PR Newswire - Thu Dec 24, 3:29PM CST
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of its previously-announced registered direct placement with healthcare focused institutional investors, for gross proceeds of $12.6 million on the terms previously announced.
NWBO: 0.47 (+0.05)
Why Northwest Biotherapeutics, Accuray, and U.S. Steel Slumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Dec 23, 5:14PM CST
Steelmakers like U.S. Steel underperformed the market today. Image: U.S. Steel. Energy stocks dominated the news Wednesday, as the price of crude oil bounced off their recent lows and raised hopes that the long slide for the industry could finally...
NWBO: 0.47 (+0.05), ARAY: 5.45 (-0.01), X: 15.91 (-0.15)
NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $12.6 MILLION
PR Newswire - Wed Dec 23, 8:00AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with healthcare focused institutional investors for a registered direct offering with gross proceeds of $12.6 million. In the offering, the Company is selling an aggregate of 3.5 million shares of common stock at a purchase price of $3.60 per share. The investors will also receive warrants to purchase up to 1.75 million shares of common stock with an exercise price of $4.50 per share. The warrants will become exercisable on the 6-month anniversary of issuance, and will have an exercise period of 5 years following the initial exercise date. The placement is expected to close on or about December 29, 2015, subject to satisfaction of customary closing conditions.
NWBO: 0.47 (+0.05)
Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020
M2 - Tue Dec 22, 6:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/q3dfhj/global_cancer) has announced the addition of the "Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020" report to their offering. The cancer industry is one of the most lucrative business worldwide. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Cancer vaccines can be broadly classified into two segments: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer. With the rising incidences of cancer and limited treatment options, physicians are being forced to look for precautionary vaccines beyond the conventional treatments. As a result, many companies are now investing in developing prophylactic and therapeutic vaccines to curb this deadly disease. In the global cancer vaccines market, the prophylactic vaccines segment account for maximum share of the market. However, the market share of prophylactic vaccines is likely to decline continuously during the forecasting period due to the increasing uptake of therapeutic vaccines. The market share of therapeutic cancer vaccines is anticipated to increase during the forecasting period. Key Topics Covered: 1. Executive Summary 2. Global - Cancer Vaccines Market and Forecast to 2020 3. Global - Cancer Vaccines Market Share and Forecast to 2020 4. Global - Prophylactic Cancer Vaccines Market and Forecast to 2020 5. Global - Therapeutics Cancer Vaccines Market and Forecast to 2020 6. Cancer Vaccines Market - Regional Analysis 7. Global Cancer Vaccines Market - Major Deals 8. Global Cancer Vaccines - Funding 9. Global Cancer Vaccines Market - Pipeline Portfolio Analysis 10. Company Cancer Vaccines - Pipeline Analysis 11. Global Cancer Vaccines Market - Driving Factors 12. Global Cancer Vaccines Market - Challenges Companies Mentioned: - Aduro Biotech - Advantagene - Advaxis - Agenus - AlphaVax - Altor BioScience - Argos Therapeutics - AVAX Technologies - Bavarian Nordic - Biothera - Celldex Therapeutics - CureVac - Galena Biopharma - Genexine - GlobeImmune - Gradalis - Heat Biologics - Immatics - ImmunoCellular Therapeutics - Inovio Pharmaceuticals - ISA Pharmaceuticals - Juvaris Biotherapeutics - NewLink Genetics - Northwest Biotherapeutics - NovaRx - OncoThyreon - Oncovir - Oxford BioMedica - Prima BioMed - Sotio - Transgene - Ubivac - Vaccinogen - Vaxon Biotech For more information visit http://www.researchandmarkets.com/research/q3...bal_cancer
HTBX: 1.39 (unch), INO: 9.24 (-0.24), ARGS: 4.90 (+0.03), NWBO: 0.47 (+0.05), ADRO: 14.67 (+0.64), CLDX: 3.65 (-0.05), NLNK: 10.77 (+0.14), GALE: 0.32 (-0.01), IMUC: 0.12 (unch)
Robbins Arroyo LLP: Northwest Biotherapeutics, Inc. (NWBO) Misled Shareholders According to a Recently Filed Class Action
BusinessWire - Mon Dec 21, 3:07PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed in the U.S. District Court for the District of Maryland. The complaint alleges that officers and directors of Northwest Biotherapeutics, Inc. (NASDAQCM: NWBO) violated the Securities Exchange Act of 1934 between March 8, 2013 and August 20, 2015, by making materially false and misleading statements about Northwest Bio's business prospects. Northwest Bio is a biotechnology company that discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
NWBO: 0.47 (+0.05)
NW Bio Announces Annual Meeting Results, Re-Election of Directors
PR Newswire - Mon Dec 21, 12:05PM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the results of its 2015 Annual Shareholder Meeting, held on Friday, December 18, 2015. There were three matters subject to a shareholder vote: the re-election of Linda Powers and Dr. Navid Malik as Directors for 3-year terms, and the re-appointment of the Company's auditors, Marcum LLP. NW Bio has a staggered Board, with one or two of the current five Directors up for re-election each year, and with each election being for a 3-year term. NWBO: 0.47 (+0.05)
Pre-Market Pulse on Biotechnology Stocks -- Inovio Pharma, Vital Therapies, Regulus Therapeutics, and Northwest Biotherapeutics
ACCESSWIRE - Mon Dec 21, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / December 21, 2015 / Park Lane Advisor has initiated coverage on the following equities: Inovio Pharmaceuticals Inc. (NASDAQ: INO), Vital Therapies Inc. (NASDAQ: VTL), Regulus Therapeutics Inc. (NASDAQ: RGLS), and Northwest Biotherapeutics Inc. (NASDAQ: NWBO). Free research report on Inovio Pharma can be accessed at http://www.parklaneadvisor.com/ On Friday, December 18, 2015, the NASDAQ Composite ended at 4,923.08, down 1.59%, the Dow Jones Industrial Average declined 2.10%, to finish the day at 17,128.55, and the S&P 500 closed at 2,005.55, down 1.78%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
INO: 9.24 (-0.24), NWBO: 0.47 (+0.05), VTL: 5.86 (+0.01), RGLS: 3.23 (-0.11)
5 Stocks We're Staying Away From in 2016
Brian Feroldi, Selena Maranjian, Sean Williams, Brian Stoffel, and Jason Hall, The Motley Fool - Motley Fool - Sun Dec 20, 7:11PM CST
Image by PeteLinforth via Pixabay. Investing in the stock market is one of the best wealth-building tools available to individual investors, as the returns provided from the market's best growth companies can be jaw dropping . Still, finding those...
PM: 98.84 (-0.91), NWBO: 0.47 (+0.05), GLD: 125.06 (-0.31), BBY: 38.00 (+0.32), SHLD: 12.12 (+0.06), PDLI: 3.17 (+0.05)
Metastatic Ovarian Cancer Pipeline Review, H2 2015 - 9 Companies & 13 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/tp9jps/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellceutix Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Immune Design Corp. - Millennium Pharmaceuticals, Inc. - Natco Pharma Limited - Northwest Biotherapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - VG Life Sciences, Inc. Drug Profiles - DCVax-Direct - DCVax-L - Drugs for Metastatic Ovarian Cancer - E-7449 - emactuzumab - G-305 - hydroxychloroquine sorafenib tosylate - KM-3174 - LV-305 - NRCAN-019 - orteronel - SM-276001 - Vaccine for Oncology For more information visit http://www.researchandmarkets.com/research/tp9jps/metastatic
IMDZ: 6.57 (+0.32), NWBO: 0.47 (+0.05)
Where We Are Headed - Featured Research on Bancorp Inc., Northwest Biotherapeutics, Xerium Technologies, and BioPharmX
ACCESSWIRE - Wed Dec 16, 7:23AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Bancorp Inc. (NASDAQ: TBBK), Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Xerium Technologies Inc. (NYSE: XRM) and BioPharmX Corp (NYSE: BPMX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 0.47 (+0.05), XRM: 8.32 (+0.15), TBBK: 6.11 (unch), BPMX: 0.65 (-0.04)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
BusinessWire - Wed Dec 16, 6:00AM CST
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and finding new ways to use the body's immune system to fight cancer.
NWBO: 0.47 (+0.05), TSRO: 104.11 (+5.32), CTMX: 15.48 (+0.37), NK: 9.23 (+0.33), CNCR: 25.65 (+0.10), SRNE: 6.93 (+0.12), XNCR: 24.63 (+0.59), ONTY: 1.21 (+0.02), CYAD: 21.45 (-1.04)
